Report Highlights

The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.

Report Includes

51 data tables and 83 additional tables

An overview of the global market for cancer therapeutics with emphasis on recurrent and metastatic divisions

Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029

Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by cancer type and region

A look at the factors driving the market’s growth and constraints

Insight into the industry value chain analysis, providing a study of the intermediaries involved

Description of cancer development stages, including the mechanisms of metastasis and recurrences, and the current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns

Coverage of causes, risk factors, prevalence and incidence of cancer, and information on its economic burden

Review of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries and radiation

Identification of the fastest-growing applications and technologies, and a review of current market trends

Discussion of the industry’s ESG challenges and practices

Review of the current market status, technology issues, industry value chain, Porter’s Five Forces, competitive landscape, R&D activity and patent analysis

Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews

Updates on recent mergers and acquisitions, facility expansions, collaborations, investments, divestments, new products and other strategic developments

Profiles of the leading vendors, including Merck & Co. Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca

Report Scope

Both qualitative and quantitative data on the current dynamics impacting the global cancer therapeutics market are presented in this report. It discusses the history of cancer, its different forms, its pathophysiology, its stages of development and its mechanisms of metastasis and recurrence. It also incorporates the disease burden by knowing the epidemiology of different cancers. Treatment patterns that include both non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, cytotoxic/chemotherapy, combinatorial therapy) approaches are discussed to illustrate the various therapeutic options available to patients.

Analyses of the most popular products, the state of clinical trials and new product approvals are also included in the report. The demographics of the major regions—North America, Europe, Asia-Pacific and the Rest of the World—as well as their prospects for growth, are summarized. The profiles of leading companies and the strategies of international businesses involved in the cancer treatment sector are also discussed.

Estimations of the market size for therapies that treat cancer metastases and recurrence states are included in the scope. Cancer types noted in this report include:

Lung.

Breast.

Liver.

Stomach.

Prostate.

Colorectal.

Gastric.

Cervical.

Bladder.

Kidney.

Ovarian.

Lymphoma.

Multiple myeloma.

Brain tumors.

Thyroid.

Uterine.

Additional growth potential and forecast data are discussed for the cancer therapeutics market, as well as for the cancer types, regions and countries.

For market estimates, data are provided for 2023 as the base year, with forecasts for the period of 2024 through 2029.